30 results about "L929 cell" patented technology

The present invention relates to a group of new oligonucleotides sequences with human tumor necrosis factor α (TNF-α) inhibiting activity, which includes DNA sequences and RNA sequences. These oligonucleotides or aptamer can specifically be bound to TNF-α and inhibit the cytoxicity of TNF-α to L929 cells. Therefore, the aptamer of the present invention may be used to detect TNF-α and provide a therapeutic method for diseases related to the increasing level of TNF-α. Compared with other TNF antagonists such as monoclonal antibody and soluble receptor, the present invention has high specificity, high affinity, quick penetration to target tissue, rapid plasma clearance, and lower immunogenecity. Turthermore, it can be used repeatedly and keeps high concentration in target tissue and the like. It has the advantages of affinity and specificity similar to monoclonal antibodies and also has permeability and pharmacokinetics characteristics similar to small molecular polypeptide. The present invention also refers to derivative of the oligonucleotides sequence, including modified sequence. The present invention may further be manufactured as medicine for therapy and diagnosis of TNF-α related diseases.

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549/DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.

The invention discloses a biodegradable Zn-Na-series zinc alloy, and belongs to the field of medical implant materials. The biodegradable Zn-Na-series zinc alloy comprises 0.01-0.97% of Na, one or more of 27 elements which are harmless or beneficial to a human body, and the balance Zn, wherein in order to lower the cost and obtain excellent comprehensive performance, the total amount of the addedvarious alloy elements is optimally controlled to be no more than 2.0%. A preparation processing process of the zinc alloy comprises the steps of continuous casting, hot extrusion and rolling; or continuous casting, hot extrusion, solidification heat treatment and drawing; or continuous casting, uniform heat treatment, hot extrusion and rolling. According to the biodegradable Zn-Na-series zinc alloy, the yield strength is 100-500 MPa, the tensile strength is 150-700 MPa, and the elongation is 1.5-100%; the degradation rate in simulated body fluid is no more than 0.8 mm/year; and the cytotoxicity to L929 cells and human mesenchymal stem cells is at the zero stage or the one stage, good biocompatibility is shown, and the biodegradable Zn-Na-series zinc alloy can be used for various medical implants.

The invention relates to a non-serum animal cell culture used fetus cattle serum displace agent, which is formed by recombination human insulin growth factor-1:0.1g-0.5g/l, recombination human platelet sourced growth factor-B:0.1g-0.6g/l, recombination human alkali desmocyte growth factor: 0.05-0.4g/l, cattle transferring: 1g-5g/l, cattle serum protein (V component): 2g-15g/l, and mercaptoethanol 0.3-0.5mol/l.

Provided is high-strength high-plasticity biodegradable Zn-Mn-Li zinc alloy. The alloy comprises 0.01-0.8% of Mn and 0.005-0.4% of Li, wherein Mn is the main alloying element, Li is the minor alloyingelement, and the content of Mn is not lower than the content of Li in the alloy; at least one of Na, K, Ca, Sr, Ti, Mg, Fe, Cu and Ag is selected, wherein the content of Na and the content of K are both not higher than 0.1%, and the total content of Na, K and Li is not higher than 0.4%; the content of Ca, the content of Sr, the content of Ti and the content of Mg are all not higher than 0.2%, andthe total content of Ca, Sr, Ti and Mg is not higher than 0.2%; the content of Fe is not higher than 0.05%; the adding amount of Cu and the adding amount of Ag are not higher than 0.4%, and the totalcontent of Cu and Ag is not higher than 0.4%; and the total content of alloy elements added into the Zn-Mn-Li zinc alloy is not higher than 1.8%, and the balance Zn. The yield strength of the zinc alloy is 250-450 MPa, the tensile strength of the zinc alloy is 350-600 MPa, and the ductility is 20-60%; the degrading rate in simulated body fluid is not higher than 0.15 mm/year; the cytotoxicity tothe L929 cell is at the level 0 or level 1, and good cytocompatibility is presented. The zinc alloy is used for a degradable bracket or other medical implants.

The invention relates to a non-serum non-animal origin protein animal cell culture used fetus cattle serum displace agent, which is formed by recombination human insulin growth factor-1:0.1g-0.5g/l, recombination human platelet sourced growth factor-B:0.1g-0.6g/l, recombination human alkali desmocyte growth factor: 0.05-0.4g/l, polyethylene glycol (MW7000-20000), 0.04-0.15%(w/v), polyvinyl alcohol (density 1.27-1.31): 0.001-0.05%(w/v), mercaptoethanol: 0.3-0.5mol/l.

The invention discloses application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of an antitumor drug. The anti-HIV drug amprenavir identified by food and drug administration (FDA) is taken as a material; the killing effect of the amprenavir on a tumor cell is detected by adopting a microwave theory and techniques (MTT) method. An experiment proves that the amprenavir has a significant inhibiting effect on multiplication of a plurality of tumor cells, such as a breast cancer michigan cancer foundation (MCF-7) cell, a non-small cell lung cancer A549 cell, a mouse embryonic fibroblast glioblastoma multiforme L929 cell, a colon cancer HT29 cell, a brain glioma U87 cell and the like, so as to clarify new use of an old drug. Therefore, foundation is provided for development of a novel anti-tumor drug.

The invention discloses boletus speciosus Frost polysaccharide BSF-X as well as a preparation method and an application thereof. The boletus speciosus Frost polysaccharide mainly comprises beta-D-glucose and alpha-D-galactose in the ratio being 2:1, has the average molecular weight of about 141309 Da, has a main chain of (1 arrow 4)-beta-D-glucose, a side chain of arrow 1,6)-alpha-D-galactose connected on 6-O and a arrow 4)-beta-D-glucose connected on galactose 2-O of the side chain. The boletus speciosus Frost polysaccharide has higher immunoregulation activity and can significantly or very significantly promote proliferation of three immune cells including B, T and Raw264.7; BSF-X can promote proliferation of cells, promote macrophage to release immune factors IL-23 and TNF-alpha, has aquite significant inhibition function on L929 in vitro and can inhibit growth of S180 tumor in vivo.

The invention provides a hybridoma fluid nutrient medium free of feeder cells. The hybridoma fluid nutrient medium free of feeder cells contains a, 20-30% in volume of a culture fluid culturing L929 cells; b, 20-30% in volume of a culture fluid culturing L6/36 cells; and c, 8-20% in volume of fetal calf serum. Compared with the prior art, the tedious process of preparing feed cells is cancelled, and the synthesized hybridoma are more easily observed and can grow and breed normally.

The present invention relates to an isoxazole derivative, the compound of formula (I)

herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027.

Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells. Moreover, GIT27-NO induced the production of reactive oxygen species which can be neutralized by antioxidant N-acetyl cysteine (NAC), indicating that reactive oxygen species (ROS) are at least partly involved in the reduction of cell viability. The anti-tumor activity of GIT27-NO is mediated through activation of MAP kinases (ERK1/2, p38 and JNK) in cell-specific manner. The role of MAP kinases was further confirmed by specific inhibitors of these molecules, PD98059, SB202190, and SP600125. Finally, in vivo treatment with GIT27-NO significantly reduced tumor growth in syngeneic C57BL/6 mice implanted with B16 melanoma.

The invention provides an extracting method for a plant composition containing valeriana officinalis. The plant composition is prepared with 100 g of the valeriana officinalis, 60 g of cissus javana, 50 g of coprinopsis atramentaria, 70 g of salix cheilophila roots and 150 g of callicarpa macrophylla leaves as raw medicinal materials. Preparing is carried out with a microwave extraction method, so that the content is greatly increased, and use amount is reduced. The invention further provides an application of the plant composition containing the valeriana officinalis in preparing medicine for inhibiting mice fibroblast L929 cell proliferation.

The invention discloses a new natural product catathelasma imperiale sing polysaccharide CIS-A and an application thereof. The catathelasma imperiale sing polysaccharide CIS-A is heteropolysaccharide composed of two monosaccharides, namely alpha-D-glucose and beta-L-galactose, in a ratio of 3:2, the average molecular weight is about 50486Da, the alpha-D-glucose connected by 1,3- and the alpha-D-glucose connected by 1,2,3- are main chains, and a side chain is the beta-L-galactose connected by two 2,3-. The catathelasma imperiale sing polysaccharide CIS-A laetiporus sulphureus polysacharride has obvious immunoregulatory activity, heteropolysaccharide CIS-A can have an obvious inhibiting effect on L929 cells cultured in vitro, and the survival rate of the cells is 68.9% when the concentration of CIS-A is 5 mu g/mL; and growth of S180 tumor is inhibited in vivo, and the inhibition ratio reaches up to 64.4%.

A new two-layer modified agar overlay cytotoxicity method for medical device safety assessment are developed. The new two layer modified agar overlay cytotoxicity method has equivalent sensitivity, and greater efficiency compared to the ISO/USP direct contact and agar overlay assays. Assays were carried out in 6-well microplates. Nutrient agar medium with a 0.5% agar concentration was used to provide a base nutrient layer to support cell growth, L929 cells mixed nutrient agar (0.33% agar) were seeded on top of the base agar and cytotoxicity was evaluated after 24 hours per USP. Results demonstrated the two layer modified agar overlay cytotoxicity assay performs as well as the ISO/USP direct contact method with distinct advantages. Results showed that this two layer modified agar overlay method is more promising as compared to the traditional agar overlay and direct contact methods due to the diluted soft agar, avoided potential mechanical damage from test materials, and represents a valuable tool to evaluate medical device cytotoxicity.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to an application of hance brandisia herb tablets to preparing medicine for suppressing proliferation of fibroblast L929 and a preparing method of the hance brandisia herb tablets. The hance brandisia herb tablets are prepared with 1,700 g of hance brandisia herbs as raw medicinal materials in a supercritical-extraction mode, and the content of acteoside is greatly increased accordingly.